-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 16th Menarini Silicon Biosystems announced new data for the DETECT research project.
data are focused on primary tumor biopsies and HER2-plus CTC in female patients with HER2-negative metastasis breast cancer (MBC).
results of this large-scale program show that HER2 plus CTC screening of blood samples from these patients is an important tool for guiding treatment decisions and improving patient prognostication.
In addition, during the 2020 San Antonio Breast Cancer Symposium, phase III, randomIZED studies discussed at the Highlights of The Poster Report showed that the addition of HER2 targeted TKI (Tyrosine kinase inhibitor) drug rapatinib to standard treatments had a positive impact on the total survival (OS) of this particular patient group.
DETECT III program is by far the largest screening analysis, taking into account the added value of CTC HER2 plus over-expression in a female HER2-negative breast cancer primary tumor biopsy to optimize patient management.
more than 1,900 HER2-negative metastasis breast cancer patients were screened for CTC counting and esothyme using menarini Silicon Biosystems' CELLSEARCH®CTC system.
CTC with anti-HER2 antibodies, then dye and classify by dyeing intensity.
the CTC HER2 status of 1159 CTC-positive patients.
174 cases (15.0%) The patient's CTC ≥ 1 and HER2 is strongly dyed.
in single-variable analysis, this is significantly related to a shorter total lifetime.
, 105 patients with CTC-HER2 staining to strong positives were included in the Phase III DETECT study and randomly assigned to the Rapatinistinist Joint Standard Treatment Group or the Standard Treatment Group.
overall survival of patients in the Rapapatinib group improved significantly.
, patients who did not observe CTC (CTC0) showed a better total lifetime (R 0.36) at the first follow-up (medium 73 days) than patients with CTC; 95% CI 0.17 - 0.76; p= 0.005)。
conclusion of the DETECT program is that CTC's HER2 over-expression and HER2 over-expression of HER2-negative primary metastasis breast cancer patients provide a key signal to doctors to consider more appropriate treatment options.
note: There are deletions in the original text
